- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr2.97 (+3.31%)Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr5.73 (-10.26%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr6.06 (-1.29%)Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr6.11Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.05 (-3.37%)Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr6.61 (+0.75%)Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr6.67 (+3.83%)Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr6.54 (+1.01%)Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr6.84 (+1.21%)Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr7.66 (+1.85%)Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr8.47 (-4.26%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr6.55 (+1.27%)Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr6.88 (+0.84%)Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr9.15 (-0.73%)Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr9.55 (+1.57%)Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr10.05 (-4.96%)Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr9.74 (-0.14%)Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr14.77 (+2.09%)Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr16.15 (-1.64%)Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr11.95 (+2.19%)Earnings
Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call Transcript
()- -
Thank you, and good morning, and welcome to today's telephone conference where we will present the study results from the Phase Ia study with MIV-818 in patients with cancer in the liver.
Joining me from Medivir today are Dr. Linda Basse, who is our Chief Medical Officer; Dr. Fredrik Oberg, who is our Director of Preclinical Research; Karin Göhlin, who is Director of Project and Portfolio Management; and Lotta Ferm, who is our Chief Financial Officer. So let's move to Slide #2. I want to start to talk a little bit about cancers in the liver. Let's say first, primary liver cancers compromise a group of very aggressive tumors characterized by large differences in geographical incidence rates. Hepatocellular carcinoma, or HCC, is the third leading cause of cancer-related deaths worldwide. It's an orphan disease in Western markets but still one of the fastest growing and most deadly cancers in the U.S. On the estimated new cases in 2018, around 610,000 are found in Asia; 42,000 in the U.S.; and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)